479 related articles for article (PubMed ID: 17868433)
41. Hepatitis A vaccine recommendations.
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2007 Jul; 120(1):189-99. PubMed ID: 17606579
[TBL] [Abstract][Full Text] [Related]
42. New viral vaccines.
Arvin AM; Greenberg HB
Virology; 2006 Jan; 344(1):240-9. PubMed ID: 16364754
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults.
Bailey CL; Smith V; Sands M
Int J Infect Dis; 2008 Nov; 12(6):e77-83. PubMed ID: 18723381
[TBL] [Abstract][Full Text] [Related]
44. [Vaccination schedule of the Spanish association of pediatrics: recommendations 2009].
Bernaola Iturbe E; Giménez Sánchez F; Baca Cots M; De Juan Martín F; Diez Domingo J; Garcés Sánchez M; Gómez-Campderá A; Martinón-Torres F; Picazo JJ; Pineda Solás V;
An Pediatr (Barc); 2009 Jan; 70(1):72-82. PubMed ID: 19174124
[TBL] [Abstract][Full Text] [Related]
45. Rocks along the road to the control of HBV and HCC.
Beasley RP
Ann Epidemiol; 2009 Apr; 19(4):231-4. PubMed ID: 19344859
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis B vaccination coverage among U.S. adolescents, National Immunization Survey-Teen, 2006.
Jain N; Hennessey K
J Adolesc Health; 2009 Jun; 44(6):561-7. PubMed ID: 19465320
[TBL] [Abstract][Full Text] [Related]
47. Cost-utility of universal hepatitis A vaccination in Canada.
Bauch CT; Anonychuk AM; Pham BZ; Gilca V; Duval B; Krahn MD
Vaccine; 2007 Dec; 25(51):8536-48. PubMed ID: 17996339
[TBL] [Abstract][Full Text] [Related]
48. Assessment of current epidemiological status of viral hepatitis in Guangdong Province, China.
Huang P; Ye G; Zhong J; Sha Q
Southeast Asian J Trop Med Public Health; 2002 Dec; 33(4):832-6. PubMed ID: 12757234
[TBL] [Abstract][Full Text] [Related]
49. Immunization and transplantation--what is new and what is coming?
Posfay-Barbe KM; Siegrist CA
Pediatr Transplant; 2009 Jun; 13(4):404-10. PubMed ID: 19032408
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in DNA vaccine of hepatitis virus.
Tang LL; Liu KZ
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):228-31. PubMed ID: 14612273
[TBL] [Abstract][Full Text] [Related]
51. Human hepatitis viruses.
Palenik CJ
J Dent Technol; 1999 Apr; 16(3):20-3. PubMed ID: 10337264
[TBL] [Abstract][Full Text] [Related]
52. A review of multiple approaches towards an improved hepatitis B vaccine.
Sanyal G; Shi L
Expert Opin Ther Pat; 2009 Jan; 19(1):59-72. PubMed ID: 19441898
[TBL] [Abstract][Full Text] [Related]
53. Viral hepatitis vaccines.
Jacobson IM; Dienstag JL
Annu Rev Med; 1985; 36():241-61. PubMed ID: 3922284
[TBL] [Abstract][Full Text] [Related]
54. [Active and passive prevention of viral hepatitis].
Jilg W
Internist (Berl); 1991 May; 32(5):249-55. PubMed ID: 1869398
[No Abstract] [Full Text] [Related]
55. Implementation of newborn hepatitis B vaccination--worldwide, 2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(46):1249-52. PubMed ID: 19023261
[TBL] [Abstract][Full Text] [Related]
56. Virus vaccines and children with asthma.
Anderson M; Carroll W
Curr Opin Allergy Clin Immunol; 2009 Feb; 9(1):44-9. PubMed ID: 19532091
[TBL] [Abstract][Full Text] [Related]
57. Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain.
Domínguez A; Oviedo M; Carmona G; Jansá JM; Borrás E; Salleras L; Plasència A
J Viral Hepat; 2008 Oct; 15 Suppl 2():51-6. PubMed ID: 18837835
[TBL] [Abstract][Full Text] [Related]
58. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis B in a high prevalence New Zealand population: a mathematical model applied to infection control policy.
Thornley S; Bullen C; Roberts M
J Theor Biol; 2008 Oct; 254(3):599-603. PubMed ID: 18644385
[TBL] [Abstract][Full Text] [Related]
60. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
